URBANDALE, Iowa, June 6, 2017 /PRNewswire/ -- Diplomat
Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. (NYSE:
DPLO), has added a sterile compounding environment to its
Iowa location.
The Iowa facility in
Urbandale now features an ISO 7
cleanroom—the standard needed to compound intravenous (IV)
nutrition formulations. A cleanroom is a controlled environment
with a low level of pollutants.
"Our new cleanroom will allow us to serve more IV nutrition
consumers and better serve our Iowa patients," said Phil Rielly, Diplomat vice president and
president of Diplomat Specialty Infusion Group. "Our goal is to
enhance consumers' quality of life through clinical excellence;
customized care; and consumer support and advocacy."
Diplomat Specialty Infusion Group is a home infusion pharmacy
providing therapies for consumers across the United States. ThriveRx, its nutrition
division, focuses on home parenteral and enteral nutrition
consumers. ThriveRx consumers receive customized Diplomat therapies
and access to nutrition experts who provide:
- Home parenteral and enteral nutrition support
- Programs designed to help consumers achieve their nutrition
goals
- Education, tools, and guidance to help them thrive
To learn more about Diplomat's specialty infusion services,
visit diplomat.is/specialtyinfusion.
Forward-Looking Statements
This press release contains
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements give current expectations or
forecasts of future events or our future financial or operating
performance. The forward-looking statements contained in this
press release are based on management's good-faith belief and
reasonable judgment based on current information. These
statements are qualified by important risks and uncertainties, many
of which are beyond our control, that could cause our actual
results to differ materially from those forecasted or indicated by
such forward-looking statements. For a discussion of such risks and
uncertainties, you should review Diplomat's filings with the
Securities and Exchange Commission, including "Risk Factors" in
Diplomat's Annual Report on Form 10-K for the year ended
Dec. 31, 2016, and in subsequent
reports filed with or furnished to the Securities and Exchange
Commission. Except as may be required by any applicable laws,
Diplomat assumes no obligation to publicly update such
forward-looking statements, which are made as of the date hereof or
the earlier date specified herein, whether as a result of new
information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) is the nation's
largest independent provider of specialty pharmacy services—helping
patients and providers in all 50 states. The company offers
medication management programs for people with complex chronic
diseases and delivers unique solutions for manufacturers,
hospitals, payors, providers, and more. Diplomat opened its doors
in 1975 as a neighborhood pharmacy with one essential tenet: "Take
good care of patients and the rest falls into place." Today, that
tradition continues—always focused on improving patient care and
clinical adherence. For more information, visit diplomat.is.
CONTACT:
Kali Lucas,
Public Relations Specialist
810.768.9580 | press@diplomat.is
Deb Pfister, ThriveRx
978.501.0801 | dpfister@diplomat.is
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/diplomat-specialty-infusion-group-now-providing-parenteral-nutrition-therapies-in-iowa-300469744.html
SOURCE Diplomat Pharmacy, Inc.